Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer

Radiotherapy and Oncology

Volumn 116, Issue 1, 2015, Pages 94-99

  Klaassen, Remy ^a   Bennink, Roelof J ^a   Van Tienhoven, Geertjan ^a   Bijlsma, Maarten F ^a   Besselink, Marc G H ^a   Van Berge Henegouwen, Mark I ^a   Wilmink, Johanna W ^a   Nederveen, Aart J ^a   Windhorst, Albert D ^b   Hulshof, Maarten C C M ^a   Van Laarhoven, Hanneke W M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hypoxia; Oesophageal cancer; Pancreatic cancer; Reproducibility; 18F HX4 PET

Indexed keywords

FLORTANIDAZOLE F 18; HX4 COMPOUND; IMIDAZOLE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TRIAZOLE DERIVATIVE;

ADULT; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; ESOPHAGUS CANCER; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PANCREAS CANCER; PATIENT MONITORING; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REPRODUCIBILITY; TREATMENT PLANNING; TREATMENT RESPONSE; AGED; ANOXIA; DIAGNOSTIC USE; ESOPHAGUS TUMOR; PANCREAS TUMOR; PATHOLOGY; PROCEDURES; SCINTISCANNING;

AGED; ANOXIA; ESOPHAGEAL NEOPLASMS; FEASIBILITY STUDIES; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; TRIAZOLES;

EID: 84938958349     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2015.05.009     Document Type: Article

References (52)

1. M. Stahl, C. Mariette, K. Haustermans, A. Cervantes, and D. Arnold Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 24 2013
2. T. Seufferlein, J.B. Bachet, E. Van cutsem, and P. Rougier Pancreatic adenocarcinoma: ESMO-ESDO clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol 23 2012
3. M. Hingorani, T. Crosby, A. Maraveyas, S. Dixit, A. Bateman, and R. Roy Neoadjuvant chemoradiotherapy for resectable oesophageal and gastro-oesophageal junction cancer-do we need another randomised trial? Clin Oncol (R Coll Radiol) 23 2011 696 705
4. G. Antoniou, P. Kountourakis, K. Papadimitriou, V. Vassiliou, and D. Papamichael Adjuvant therapy for resectable pancreatic adenocarcinoma: review of the current treatment approaches and future directions Cancer Treat Rev 40 2014 78 85
5. V. Heinemann, M. Haas, and S. Boeck Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer Ann Oncol 24 2013 2484 2492
6. O.E. Rahma, A. Duffy, D.J. Liewehr, S.M. Steinberg, and T.F. Greten Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials Ann Oncol 24 2013 1972 1979
7. M. Winther, J. Alsner, T. Tramm, and M. Nordsmark Hypoxia-regulated gene expression and prognosis in loco-regional gastroesophageal cancer Acta Oncol 52 2013 1327 1335
8. D. Mahadevan, and D.D. Von Hoff Tumor-stroma interactions in pancreatic ductal adenocarcinoma Mol Cancer Ther 6 2007 1186 1197
9. M. Erkan, C. Reiser-Erkan, and C. Michalski Cancer-stellate cell interactions perpetuate the hypoxia-fibrosis cycle in pancreatic ductal adenocarcinoma Neoplasia 11 2009 497 508
10. A.C. Koong, V.K. Mehta, Q.T. Le, G.A. Fisher, D.J. Terris, J.M. Brown, and et al. Pancreatic tumors show high levels of hypoxia Int J Radiat Oncol Biol Phys 48 2000 919 922
11. W. Ping, W. Sun, Y. Zu, W. Chen, and X. Fu Clinicopathological and prognostic significance of hypoxia-inducible factor-1alpha in esophageal squamous cell carcinoma: a meta-analysis Tumour Biol 2014 4401 4409
12. K. Kasuya, A. Tsuchida, Y. Nagakawa, M. Suzuki, Y. Abe, T. Itoi, and et al. Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer Oncol Rep 26 2011 1399 1406
13. D.M. Brizel, S.P. Scully, J.M. Harrelson, L.J. Layfield, J.M. Bean, L.R. Prosnitz, and et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma Cancer Res 56 1996 941 943
14. M. Höckel, C. Knoop, K. Schlenger, B. Vorndran, E. Baussmann, M. Mitze, and et al. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix Radiother Oncol 26 1993 45 50
15. M. Höckel, and P. Vaupel Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects J Natl Cancer Inst 93 2001 266 276
16. L. Saksø, M. Busk, M. Nordsmark, S. Jakobsen, J. Theil, J. Overgaard, and et al. Accessing radiation response using hypoxia PET imaging and oxygen sensitive electrodes: A preclinical study 99 2011 418 423
17. L.H. Gray, A.D. Conger, M. Ebert, S. Hornsey, and O.C.A. Scott The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy Br J Radiol 26 1953 638 648
18. B. Singers, M. Busk, N. Olthof, E. Speel, M.R. Horsman, J. Alsner, and et al. Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells 108 2013 500 505
19. S. Servagi-Vernat, S. Differding, E. Sterpin, F. Hanin, D. Labar, A. Bol, and et al. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study Acta Oncol (Madr) 1-9 2015
20. D. Thorwarth, S.M. Eschmann, F. Paulsen, and M. Alber Hypoxia dose painting by numbers: a planning study Int J Radiat Oncol Biol Phys 68 2007 291 300
21. J. Henk, K. Bischop, and S. Shepherd Treatment of head and neck cancer with CHART and nimorazole: phase II study Radiother Oncol 66 2003 65 70
22. J. Overgaard Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - a systematic review and meta-analysis Radiother Oncol 100 2011 22 32
23. J. Overgaard The heat is (still) on - the past and future of hyperthermic radiation oncology Radiother Oncol 109 2013 185 187
24. M.J. Borad Randomized phase II trial of gemcitabine plus TH-302 versus gemcitabine in patients with advanced pancreatic Cancer J Clin Oncol 32 2014 1 8
25. W.R. Wilson, and M.P. Hay Targeting hypoxia in cancer therapy Nat Rev Cancer 11 2011 393 410
26. L.S. Mortensen, J. Johansen, J. Kallehauge, H. Primdahl, M. Busk, P. Lassen, and et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial Radiother Oncol 105 2012 14 20
27. 18F-FAZA PET imaging for guiding the association of radiotherapy with nimorazole: a preclinical study Radiother Oncol 2015
28. 18F-FAZA PET to guide hypoxia-driven interventions (carbogen breathing or dose escalation) in radiation therapy Radiother Oncol 113 2014 204 209
29. M.R. Horsman, L.S. Mortensen, J.B. Petersen, M. Busk, and J. Overgaard Imaging hypoxia to improve radiotherapy outcome Nat Rev Clin Oncol 9 2012 674 687
30. 18)F]-2-fluoro-2'-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia Strahlenther Onkol 180 2004 616 622
31. K.A. Krohn, J.M. Link, and R.P. Mason Molecular imaging of hypoxia J Nucl Med 49 2008 129S 148S
32. E. Lopci, I. Grassi, A. Chiti, and C. Nanni PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence Nucl Med Mol Imaging 4 2014 365 384
33. 18F]HX4, a promising hypoxia marker for PET imaging Proc Natl Acad Sci U S A 108 2011 14620 14625
34. M. Doss, J.J. Zhang, M.-J. Bélanger, J.B. Stubbs, E.D. Hostetler, K. Alpaugh, and et al. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT Nucl Med Commun 31 2010 1016 1024
35. 18F]HX4: a phase I trial Eur J Nucl Med Mol Imaging 37 2010 1663 1668
36. C.M.L. Zegers, W. van Elmpt, R. Wierts, B. Reymen, H. Sharifi, M.C. Ollers, and et al. Hypoxia imaging with [(18)F]HX4 PET in NSCLC patients: defining optimal imaging parameters Radiother Oncol 109 2013 58 64
37. 18F]FMISO in a Preclinical Tumor Model Int J Radiat Oncol 91 2015 351 359
38. 18F-FMISO Nucl Med Commun 33 2012 1096 1102
39. S. Carlin, H. Zhang, M. Reese, N.N. Ramos, Q. Chen, and S.-A. Ricketts A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers J Nucl Med 55 2014 515 521
40. S. Klein, M. Staring, K. Murphy, M.A. Viergever, and J.P.W. Pluim Elastix: a toolbox for intensity-based medical image registration IEEE Trans Med Imaging 29 2010 196 205
41. J.M. Bland, and D.G. Altman Statistical methods for assessing agreement between two methods of clinical measurement Lancet 1 1986 307 310
42. V.R. Bollineni, M.J.B. Koole, J. Pruim, C.L. Brouwer, E.M. Wiegman, H.J.M. Groen, and et al. Dynamics of tumor hypoxia assessed by (18)F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies Radiother Oncol 113 2014 198 203
43. S. Servagi-Vernat, S. Differding, F.-X. Hanin, D. Labar, A. Bol, J.A. Lee, and et al. A prospective clinical study of (18) F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy Eur J Nucl Med Mol Imaging 41 2014 1544 1552
44. 18F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma Mol Imaging Biol 13 2011 227 231
45. 18F-fluoromisonidazole positron emission tomography and computed tomography (f-miso pet/ct) before and during radiation therapy J Radiat Res 54 2013 1078 1084
46. D. Zips, K. Zöphel, N. Abolmaali, R. Perrin, A. Abramyuk, R. Haase, and et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer Radiother Oncol 105 2012 21 28
47. 18F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study Dis Esophagus 25 2012 54 61
48. 18F-FMISO) PET/CT in suspected or proven pancreatic cancer Clin Nucl Med 38 2013 1 6
49. 18F -fluoromisonidazole PET for head and neck cancer J Nucl Med 54 2013 201 207
50. 18F-FDG uptake measurements in tumors: a metaanalysis J Nucl Med 53 2012 701 708
51. J. Sato, Y. Kitagawa, Y. Yamazaki, H. Hata, T. Asaka, M. Miyakoshi, and et al. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma Eur J Nucl Med Mol Imaging 41 2014 2031 2041
52. M. Clausen, A. Hansen, M. Lundemann, C. Hollensen, T. Pommer, P. Munck af Rosenschöld, and et al. Dose painting based on tumor uptake of Cu-ATSM and FDG: a comparative study Radiat Oncol 9 2014 228